These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

262 related articles for article (PubMed ID: 28980665)

  • 21. Cholesteryl ester transfer protein inhibitors in the treatment of dyslipidemia: a systematic review and meta-analysis.
    Li C; Zhang W; Zhou F; Chen C; Zhou L; Li Y; Liu L; Pei F; Luo H; Hu Z; Cai J; Zeng C
    PLoS One; 2013; 8(10):e77049. PubMed ID: 24204732
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Dissociating HDL cholesterol from cardiovascular risk.
    Hausenloy DJ; Opie L; Yellon DM
    Lancet; 2010 Jul; 376(9738):305-6. PubMed ID: 20655104
    [No Abstract]   [Full Text] [Related]  

  • 23. Patient considerations and clinical impact of cholesteryl ester transfer protein inhibitors in the management of dyslipidemia: focus on anacetrapib.
    Miyares MA; Davis K
    Vasc Health Risk Manag; 2012; 8():483-93. PubMed ID: 22977305
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Raising HDL with CETP inhibitor torcetrapib improves glucose homeostasis in dyslipidemic and insulin resistant hamsters.
    Briand F; Prunet-Marcassus B; Thieblemont Q; Costard C; Muzotte E; Sordello S; Sulpice T
    Atherosclerosis; 2014 Apr; 233(2):359-362. PubMed ID: 24530763
    [TBL] [Abstract][Full Text] [Related]  

  • 25. CETP Inhibition in CVD Prevention: an Actual Appraisal.
    Di Bartolo B; Takata K; Duong M; Nicholls SJ
    Curr Cardiol Rep; 2016 May; 18(5):43. PubMed ID: 27002619
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cholesteryl Ester Transfer Protein Inhibition for Preventing Cardiovascular Events: JACC Review Topic of the Week.
    Armitage J; Holmes MV; Preiss D
    J Am Coll Cardiol; 2019 Feb; 73(4):477-487. PubMed ID: 30704580
    [TBL] [Abstract][Full Text] [Related]  

  • 27. When good cholesterol turns bad: the evolving saga of CETP inhibitors and clinical strategies to elevate high-density lipoprotein.
    Oram JF; Heinecke JW
    Curr Atheroscler Rep; 2007 Dec; 9(6):425-7. PubMed ID: 18377780
    [No Abstract]   [Full Text] [Related]  

  • 28. Efficacy and safety of dalcetrapib in type 2 diabetes mellitus and/or metabolic syndrome patients, at high cardiovascular disease risk.
    Stalenhoef AF; Davidson MH; Robinson JG; Burgess T; Duttlinger-Maddux R; Kallend D; Goldberg AC; Bays H
    Diabetes Obes Metab; 2012 Jan; 14(1):30-9. PubMed ID: 21819519
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Treating high-density lipoprotein cholesterol: a return to inhibition of cholesteryl ester transfer protein?
    Duriez P
    Curr Atheroscler Rep; 2008 Jun; 10(3):177-9. PubMed ID: 18489843
    [No Abstract]   [Full Text] [Related]  

  • 30. Unending saga of fighting cholesterol: Evacetrapib is another fallen warrior.
    Simko V
    Bratisl Lek Listy; 2016; 117(11):625-627. PubMed ID: 28125886
    [TBL] [Abstract][Full Text] [Related]  

  • 31. No cardiovascular benefit with evacetrapib - is this the end of the road for the 'cetrapibs'?
    Doggrell SA
    Expert Opin Pharmacother; 2017 Oct; 18(14):1439-1442. PubMed ID: 28799819
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Treatment of dyslipidemia - is here still place for CETP-inhibitors?].
    Murín J; Pernický M; Kiňová S
    Vnitr Lek; 2016; 62(10):789-794. PubMed ID: 27900865
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Spotlight on HDL-raising therapies: insights from the torcetrapib trials.
    Kontush A; Guérin M; Chapman MJ
    Nat Clin Pract Cardiovasc Med; 2008 Jun; 5(6):329-36. PubMed ID: 18431367
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cholesteryl ester transfer protein (CETP) inhibitors.
    Hunt JA; Lu Z
    Curr Top Med Chem; 2009; 9(5):419-27. PubMed ID: 19519458
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Is a blood pressure rise the only deleterious off-target effect of cholesterol ester transfer protein inhibitors?
    Miura S; Saku K
    J Hypertens; 2010 Aug; 28(8):1614-6. PubMed ID: 20647856
    [No Abstract]   [Full Text] [Related]  

  • 36. The therapeutic potential of CETP inhibitors: a patent review.
    Wang X; Li W; Hao L; Xie H; Hao C; Liu C; Li W; Xiong X; Zhao D
    Expert Opin Ther Pat; 2018 Apr; 28(4):331-340. PubMed ID: 29424255
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Refocusing on use of cholesteryl ester transfer protein inhibitors.
    Kastelein JJ
    Am J Cardiol; 2007 Dec; 100(11 A):n47-52. PubMed ID: 18047853
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Future of cholesteryl ester transfer protein (CETP) inhibitors: a pharmacological perspective.
    Mohammadpour AH; Akhlaghi F
    Clin Pharmacokinet; 2013 Aug; 52(8):615-26. PubMed ID: 23658137
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Synthesis, Biological Evaluation, and Molecular Modeling Study of Substituted Benzyl Benzamides as CETP Inhibitors.
    Abu Khalaf R; Sabbah D; Al-Shalabi E; Bishtawi S; Albadawi G; Abu Sheikha G
    Arch Pharm (Weinheim); 2017 Dec; 350(12):. PubMed ID: 29112287
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Current status of CETP inhibitors in the treatment of hyperlipidemia: an update.
    Ghosh RK; Ghosh SM
    Curr Clin Pharmacol; 2012 May; 7(2):102-10. PubMed ID: 22432840
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.